Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
Conditions
- Recurrent Uterine Corpus Sarcoma
- Uterine Corpus Leiomyosarcoma
Interventions
- DRUG: Alisertib
- OTHER: Laboratory Biomarker Analysis
Sponsor
National Cancer Institute (NCI)
Collaborators